Mean ± standard deviation hematologic parameters over time (n = 33*). (A) platelet count, (B) absolute neutrophil count, (C) hemoglobin level, and (D) percentage of bone marrow blasts over time. *One patient enrolled in dose-escalation phase was positive for the IDH1-D54N mutation by local testing and was not positive for the IDH1-R132 mutation by the companion diagnostic test; this patient was therefore excluded from the efficacy analyses.